Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Sep
21
Today In Oncology
Losing Weight and Breast Cancer Risk? The GLP-1 Question
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer
NCCN Releases New Guideline for Patients and Caregivers: Older Adults With Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo